Dr. Sweetser and colleagues reply

New England Journal of Medicine

Volumn 369, Issue 11, 2013, Pages 1082-

  Sweetser, Marianne T ^a   Dawson, Katherine T ^a   Bozic, Carmen ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUMADERM; DERMATOLOGICAL AGENT; FUMARIC ACID DERIVATIVE;

DRUG WITHDRAWAL; HUMAN; LETTER; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; SARCOIDOSIS; CHEMICALLY INDUCED DISORDER; FEMALE; IMMUNE DEFICIENCY; MALE; NOTE;

DERMATOLOGIC AGENTS; FEMALE; FUMARATES; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE;

EID: 84884303937     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1307680     Document Type: Letter

References (2)

1. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23:Suppl 2:1-70. [Erratum, J Eur Acad Dermatol Venereol 2010;24:117-8.]
2. Nast A, Boehncke WH, Mrowietz U, et al. S3 - guidelines on the treatment of psoriasis vulgaris (English version): update. J Dtsch Dermatol Ges 2012;10:Suppl 2:S1-S95.